Beacon Capital Management LLC (Tennessee)’s Galectin Therapeutics GALT Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23,905	Closed	-$50.4K	–	463
2025 Q2	$50.4K	Hold	23,905	–	–	0.01%	331
2025 Q1	$29.2K	Hold	23,905	–	–	﹤0.01%	407
2024 Q4	$30.8K	Hold	23,905	–	–	﹤0.01%	386
2024 Q3	$65.7K	Hold	23,905	–	–	0.01%	278
2024 Q2	$54K	Hold	23,905	–	–	0.01%	274
2024 Q1	$57.1K	Hold	23,905	–	–	0.01%	272
2023 Q4	$45.9K	Buy	23,905 +11,300	+90%	+$21.9K	0.01%	234
2023 Q3	$18.2K	Hold	12,605	–	–	﹤0.01%	426
2023 Q2	$18.2K	Hold	12,605	–	–	﹤0.01%	426
2023 Q1	$26.5K	Hold	12,605	–	–	0.01%	321
2022 Q4	$14.2K	Buy	+12,605	New	+$16.8K	﹤0.01%	433

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s GALT Position: Q3 2025 in Review

Beacon Capital Management LLC (Tennessee) sold out of Galectin Therapeutics (GALT) in Q3 2025, closing a stake of 23,905 shares — an estimated $50.4K sold.

Beacon Capital Management LLC (Tennessee) first reported a position in GALT in Q4 2022 and held it in 11 quarters. The position peaked at $65.7K in Q3 2024. 84 funds tracked by Wall St. Rank hold GALT as of Q3 2025.

Beacon Capital Management LLC (Tennessee) reported no remaining Galectin Therapeutics position as of Q3 2025 after selling out during the quarter.
Beacon Capital Management LLC (Tennessee) sold 23,905 Galectin Therapeutics shares in Q3 2025, an estimated $50.4K.
Beacon Capital Management LLC (Tennessee) first reported a position in Galectin Therapeutics in Q4 2022 and held it in 11 quarters.
Beacon Capital Management LLC (Tennessee)'s Galectin Therapeutics position peaked at $65.7K in Q3 2024.
84 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2025.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q3 2025, filed 7 Nov 2025.